10 Jun 2013, BioSpectrum Bureau , BioSpectrum
Singapore: US pharmaceutical major, Eli Lilly and Company, said that they expect to be among the top 20 drug makers in India by 2020. The company hopes to climb the growth ladder by strenghtening its presence in core segments like diabetes, oncology, cardiovascular, neuro sciences, women's health, men's health and auto-immune diseases.
"We are aiming to become one of the top 20 pharma companies in India by 2020. We are at about 50th position at present," said CMD of Eli Lilly, Dr Melt Van Der Spuy.
Dr Spuy frther highlighted that the company will increase workforce, expand portfolios and make new launches to expand its business. The company will be launching its innovative insulin delivery device 'Savvio' in the Indian market in August 2013.
Apart from India, the company said that Indonesia and Vietnam are the other high growth markets that the company will be targetting. "It is a very important country for the company. We see tremendous growth prospects here," said Ms Jannie Oosthuizen, president, Eli Lilly Asia Operations.